USP22 and hepatocellular carcinoma: In addition of USP22, USP29 also deubiquitinates HIF1α, contributing to sorafenib resistance in HCC cells by promoting the transcriptional activation of target genes, especially hexokinase 2 (HK2), a key enzyme in glycolytic pathway [168].